Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.
- Revenue
- +1.33%
- EPS
- +418.2%
- Free cash flow
- −6.83%
- Total debt
- −42.2%
Quarter to June 2026, against a year earlier
Follow TECH
Alert me
Bio-Techne Corp (TECH) P/E ratio
As of 5 November 2026, Bio-Techne Corp (TECH) trades at a P/E ratio of 62.2×. Over the past ten years it has ranged from 28.5× (January 2015) to 148× (September 2021); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of 10.3× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 60.4× | (46.01%) |
| FY2025 | 112× | 65.56% |
| FY2024 | 67.6× | 50.62% |
| FY2023 | 44.9× | (10.20%) |
| FY2022 | 49.9× | (59.73%) |
| FY2021 | 124× | 181.83% |
| FY2020 | 44.0× | (46.79%) |
| FY2019 | 82.7× | 86.38% |
| FY2018 | 44.4× | (26.36%) |
| FY2017 | 60.3× | 50.19% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 60.4× | (17.96%) |
| Mar 2026 | 73.6× | (34.92%) |
| Dec 2025 | 113× | 1.65% |
| Sep 2025 | 111× | (0.53%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TWST Twist Bioscience Corporation compare | n/m |
| IBRX ImmunityBio, Inc. compare | n/m |
| KYMR Kymera Therapeutics, Inc. compare | n/m |
| BMRN BioMarin Pharmaceutical Inc. compare | n/m |
| SMMT Summit Therapeutics PLC compare | n/m |
| PCVX Vaxcyte, Inc. compare | n/m |
| TGTX TG Therapeutics, Inc. compare | 19.1× |
| TECH Bio-Techne Corp | 62.2× |
| CAI Caris Life Sciences,�Inc. compare | 77.7× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement